Home Breast Cancer Biomarkers ESR1 Mutation Test for Breast Cancer: Hormone Resistance Marker, Recurrence, and Mutation...

ESR1 Mutation Test for Breast Cancer: Hormone Resistance Marker, Recurrence, and Mutation Meaning

By
Vita Library
-
1
ESR1 mutation testing explained: hormone resistance, ctDNA detection, positive and negative results, oral SERDs, recurrence limits, and 2026 treatment guidance.

An ESR1 mutation test looks for acquired changes in the gene that encodes estrogen receptor alpha, a major driver of hormone receptor-positive breast cancer. These mutations are uncommon in untreated primary tumors but can emerge under the selective pressure of aromatase-inhibitor therapy in advanced disease. Once present, certain ESR1 mutations can keep the estrogen receptor active even when estrogen levels are very low, making aromatase inhibitors less effective. The mutation is usually tested in circulating tumor DNA (ctDNA) from plasma because blood can capture resistant clones from multiple metastatic sites and can be repeated over time. In 2026, ESR1 testing gained a new treatment-timing role: the FDA granted accelerated approval to camizestrant plus a CDK4/6 inhibitor when an ESR1 mutation is detected during first-line aromatase-inhibitor plus CDK4/6 therapy before imaging progression. ESR1 testing should therefore be interpreted in the exact treatment context rather than as a general recurrence test.

  • ESR1 mutations are usually acquired tumor mutations, not inherited hereditary-breast-cancer variants.
  • They most often emerge in ER-positive/HER2-negative advanced breast cancer after exposure to aromatase inhibitors.
  • Plasma ctDNA is the preferred practical method for detecting ESR1 mutations in many advanced-disease settings because mutations can be heterogeneous.
  • An ESR1 mutation suggests resistance to aromatase-inhibitor estrogen deprivation but does not mean all endocrine therapy will fail.
  • As of September 2026, FDA-authorized ESR1 ctDNA detection can trigger a camizestrant-plus-CDK4/6 switch before imaging progression in a defined first-line setting.

Table of Contents

What ESR1 Mutations Are

ESR1 is the gene that encodes estrogen receptor alpha, the protein measured by routine ER immunohistochemistry. In an ER-positive breast cancer, estrogen receptor signaling can drive tumor growth. Aromatase inhibitors reduce estrogen production and can suppress this pathway very effectively, but cancer cells can evolve under prolonged treatment pressure.

Certain mutations in the ligand-binding domain of ESR1 change the receptor’s shape so that it remains active even when estrogen is scarce. Common hotspot mutations include changes around codons Y537 and D538, although panels may detect additional activating variants. These are somatic changes in the tumor, not usually inherited germline variants.

That distinction matters. A positive ESR1 mutation does not imply a 50% chance that a child or sibling carries the same change, and it does not replace hereditary BRCA testing. Family-risk counseling is not based on a typical acquired ESR1 resistance mutation.

ESR1 mutation is also different from the ER IHC test. ER IHC asks whether tumor-cell nuclei express estrogen receptor protein. ESR1 sequencing asks whether the receptor gene has acquired an activating mutation. A tumor can remain strongly ER-positive by IHC while carrying an ESR1 mutation that makes it resistant to a particular endocrine strategy.

These mutations are particularly important in metastatic disease because they can appear after years of endocrine therapy and may be present in some metastatic clones but not others.

When ESR1 Testing Is Used

The main use of ESR1 testing is in ER-positive, HER2-negative advanced or metastatic breast cancer after endocrine exposure. ASCO’s 2023 rapid recommendation update supported testing for ESR1 mutations to guide therapy in this setting and favored blood-based ctDNA because mutations can evolve and become detectable over time.

Testing is not generally useful at the initial diagnosis of an untreated early-stage ER-positive tumor because ESR1 hotspot mutations are uncommon before endocrine selection pressure. A negative result at diagnosis would not guarantee that a mutation will never emerge later.

Historically, testing was often performed at disease progression to help select a next endocrine therapy, particularly an oral selective estrogen receptor degrader (SERD). The 2023 FDA approval of elacestrant established a clear post-progression treatment role for ESR1-mutated ER-positive/HER2-negative advanced breast cancer after prior endocrine therapy.

The 2025 SERENA-6 trial changed the timing question. Investigators repeatedly tested ctDNA every two to three months during first-line aromatase-inhibitor plus CDK4/6 treatment. Patients with a newly detected ESR1 mutation but no radiologic progression were randomized to switch the endocrine partner to camizestrant or continue the aromatase inhibitor while maintaining the CDK4/6 inhibitor. The switch improved progression-free survival.

On September 4, 2026, the FDA granted accelerated approval to camizestrant in that specific scenario, with an FDA-authorized ESR1 test. This is not a blanket recommendation to screen every patient with ESR1 testing at any interval; it is a defined treatment-linked use.

How ESR1 Testing Is Performed

ESR1 mutations can be tested in tumor tissue or in plasma ctDNA. Plasma has practical advantages in advanced breast cancer: it avoids an invasive biopsy, can be repeated over time, and can capture DNA shed by several metastatic sites. This is especially useful for acquired resistance because different metastases may contain different ESR1 clones.

Assays use techniques such as digital PCR or next-generation sequencing. Some target common ESR1 hotspots with high sensitivity, while broader panels evaluate ESR1 together with PIK3CA, AKT1, PTEN, ERBB2, BRCA1/2, and many other cancer genes. The best assay depends on the treatment question.

A blood sample requires careful processing because ctDNA is only a small fraction of total cell-free DNA. Low tumor shedding can produce a false-negative result. If plasma testing is negative but the result is crucial and clinical suspicion remains, tissue testing or repeat plasma testing may be appropriate according to the situation.

The report should name the exact ESR1 variant and may include variant allele frequency. The allele frequency is the proportion of sequencing reads containing the variant, not the percentage of tumor cells carrying it. It is influenced by the amount of tumor DNA in plasma, copy number, clone size, and technical factors.

For the 2026 camizestrant indication, the treatment decision must be based on an FDA-authorized companion diagnostic. A research assay that detects an ESR1 mutation is biologically informative, but regulatory treatment eligibility can depend on the approved testing framework.

What a Positive ESR1 Result Means

A positive activating ESR1 mutation means the cancer has developed a known endocrine-resistance mechanism. The mutated receptor can signal with reduced dependence on estrogen, which undermines the mechanism of aromatase inhibitors. That is why continuing the same aromatase inhibitor may become less effective once the resistant clone expands.

The result does not mean the cancer is resistant to every endocrine therapy. SERDs work differently by binding and destabilizing or degrading the estrogen receptor. Randomized trials have shown activity of oral SERDs in ESR1-mutated disease, and the treatment effect can be stronger in the mutation-positive subgroup than in ESR1 wild-type disease.

At progression after prior endocrine therapy, elacestrant is one established ESR1-directed option under its indication. In the earlier first-line setting addressed by SERENA-6 and the 2026 FDA accelerated approval, the strategy is to switch from the aromatase inhibitor to camizestrant while continuing the CDK4/6 inhibitor when ESR1 emerges before radiologic progression.

The mutation also has prognostic and evolutionary meaning. It shows that the tumor is adapting under endocrine pressure. Multiple ESR1 mutations can coexist in the same patient, reflecting parallel resistant clones. A broad plasma assay may detect several hotspot variants at once.

A positive result should therefore lead to a treatment-context discussion, not a generalized statement that the cancer has “become hormone negative.” Many ESR1-mutant tumors still express ER protein and remain dependent enough on the receptor to respond to a different ER-directed drug.

What a Negative ESR1 Result Means

A negative ESR1 result means no reportable mutation was detected in that sample at that time. It does not prove that the tumor is fully endocrine sensitive and does not rule out other resistance mechanisms.

ER-positive breast cancer can resist endocrine therapy through changes in PI3K/AKT/mTOR signaling, receptor crosstalk, cell-cycle pathways, loss of ER expression, altered co-regulators, or other genomic events. A patient can therefore have progressive disease with ESR1 wild-type ctDNA.

A plasma false negative is also possible. Tumor DNA shedding can be low, particularly when disease volume is small or predominantly located in sites that release little DNA into blood. Assay sensitivity and the specific mutations covered also matter. A negative result that conflicts with clear progression should not override imaging and clinical assessment.

Timing is critical. ESR1 may be negative early in first-line therapy and become positive months later as a resistant clone expands. That is why the SERENA-6 strategy used scheduled serial testing rather than a single baseline test. Repeating testing only makes sense when there is a defined action for a newly positive result.

A negative ESR1 result should also not be interpreted as a reason to use an aromatase inhibitor indefinitely. Treatment decisions depend on the total clinical picture, prior therapy, duration of benefit, disease sites, other actionable mutations, and patient preferences.

ESR1 Mutations and Oral SERD Treatment

Selective estrogen receptor degraders are designed to antagonize and promote degradation of the estrogen receptor. Fulvestrant was the first widely used SERD but requires intramuscular injections. Newer oral SERDs were developed to achieve more convenient dosing and, in some cases, improved activity against mutant estrogen receptors.

The phase III EMERALD trial established elacestrant as an oral option after progression on prior endocrine therapy and CDK4/6 inhibition. The benefit was particularly relevant in the ESR1-mutated population, leading to FDA approval for postmenopausal women and adult men with ER-positive/HER2-negative, ESR1-mutated advanced or metastatic breast cancer after at least one line of endocrine therapy.

SERENA-6 addressed a different question: whether to act before imaging progression when an ESR1 mutation first appears in ctDNA during aromatase-inhibitor plus CDK4/6 treatment. Median progression-free survival was 16.0 months after switching to camizestrant versus 9.2 months with continued aromatase inhibitor in the trial. The FDA’s 2026 accelerated approval followed this molecularly triggered strategy.

Because the approval is accelerated, confirmatory evidence is still required to verify clinical benefit. The FDA explicitly noted that it is not yet confirmed whether intervening at the molecular-resistance stage, rather than waiting for confirmed progression, translates into a clinically meaningful long-term benefit such as improved survival.

Other oral SERDs and combinations continue to evolve. ESR1 status is therefore likely to remain a dynamic biomarker whose treatment implications depend on the specific drug, line of therapy, prior CDK4/6 exposure, and current regulatory label.

ESR1 Is Not a General Recurrence Test

Because ESR1 can be detected in ctDNA, it is easy to confuse an ESR1 mutation test with a general test for breast cancer recurrence. They are not the same. ESR1 testing looks for a particular acquired resistance mechanism in a defined subtype of breast cancer.

A patient with early-stage breast cancer who has completed curative treatment should not have routine ESR1 blood testing simply to look for hidden recurrence. Current ASCO surveillance guidance does not recommend routine ctDNA recurrence monitoring for all breast cancer survivors, and ESR1 would miss many recurrences because not all tumors are ER-positive and not all endocrine-resistant tumors develop ESR1 mutations.

Even in metastatic ER-positive disease, the mutation does not measure total cancer burden. A low variant allele frequency can be clinically important if it represents an emerging resistant clone, while a high frequency may simply reflect higher ctDNA shedding. The value should not be treated as a tumor-volume percentage.

The new 2026 indication is narrow but important: serial ctDNA detection of ESR1 during ongoing first-line aromatase-inhibitor plus CDK4/6 therapy can trigger an evidence-based switch before radiologic progression. That is resistance monitoring tied to a specific intervention, not generic recurrence screening.

Keeping those uses separate prevents overtesting. A biomarker is most valuable when clinicians know exactly what biological question it answers and what action is supported when the answer changes.

Questions to Ask About an ESR1 Mutation Result

Ask first whether the mutation was found in plasma ctDNA or tumor tissue and whether the assay is validated for the treatment being considered. For a companion-diagnostic indication, confirm that the test meets the regulatory requirement.

Ask which exact ESR1 variant was detected and whether it is a recognized activating hotspot. If multiple variants are present, ask whether that changes the treatment interpretation. The gene name alone is less informative than the variant classification and clinical context.

Next, ask when the mutation appeared. Was it found at radiologic progression after prior endocrine therapy, or did it emerge during first-line aromatase-inhibitor plus CDK4/6 therapy while scans were still stable? Those scenarios can lead to different treatment options.

If the result is negative, ask whether low ctDNA could have limited sensitivity and whether another resistance mechanism was found. A broad plasma panel may reveal PIK3CA, AKT1, PTEN, or other alterations that create a different targeted-therapy path.

For the 2026 camizestrant strategy, ask about the accelerated-approval status, expected progression-free survival benefit, side effects, drug interactions, and what confirmatory evidence is still being gathered. The FDA label also includes important safety information that should be reviewed before treatment.

Finally, do not interpret ESR1 as hereditary. If the family history raises concern for inherited cancer risk, germline testing should be addressed separately. An ESR1 resistance mutation is primarily a map of how the tumor has evolved under treatment.

Where ESR1 testing fits across the treatment timeline

The usefulness of ESR1 depends strongly on when the sample is taken. At initial diagnosis of untreated early-stage breast cancer, acquired ESR1 hotspot mutations are uncommon, so routine ESR1 sequencing usually does not add meaningful information. The tumor’s ER IHC result, HER2 status, stage, and standard genomic risk tools are more relevant at that point.

During metastatic endocrine therapy, the situation changes. Aromatase inhibition creates selection pressure that can favor pre-existing or newly emerging ESR1-mutant clones. Serial plasma ctDNA can detect that evolution before a large amount of disease is visible on imaging. The 2026 camizestrant approval makes this concept actionable in one defined first-line setting: HR-positive/HER2-negative locally advanced or metastatic disease treated with an aromatase inhibitor plus CDK4/6 inhibitor, with an ESR1 mutation detected by an FDA-authorized test before radiologic progression.

At confirmed progression after prior endocrine therapy, ESR1 can support selection of an oral SERD such as elacestrant when the patient meets the drug’s indication. At the same time, broader molecular testing may reveal PIK3CA, AKT1, PTEN, germline BRCA-related findings, or other alterations that compete with or complement the ESR1-directed option.

This timeline prevents overgeneralization. ESR1 is not a universal screening marker, not a hereditary-risk test, and not a stand-alone measure of tumor burden. Its value comes from matching an acquired resistance mutation to a treatment decision at the point when that decision is supported by clinical evidence and the applicable regulatory label.

Serial testing should also have a defined stopping or action rule. Repeating ctDNA every few months makes sense only when the patient fits a treatment pathway in which emerging ESR1 changes management. Testing without an actionable plan can produce anxiety and extra cost while offering no clear clinical benefit. The oncology team should specify what result would trigger a switch, what assay is acceptable, how imaging will continue, and how other signs of progression will be handled. That turns ESR1 testing from a stand-alone laboratory exercise into a controlled treatment-monitoring strategy.

References

Disclaimer

This article provides general information about ESR1 mutation testing in breast cancer. ESR1 results should be interpreted by an oncology team in the context of disease stage, treatment history, assay type, other biomarkers, current FDA indications, and the patient’s overall treatment goals.

RELATED ARTICLESMORE FROM AUTHOR